Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumiliximab plus FCR versus FCR alone in previously untreated CLL
2008-002204-25Phase 2Terminated
- Sponsor
- Biogen
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lumiliximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Biogen. Primary endpoint: Safety and tolerability. Started Nov 2008; status: terminated.
02
Drugs
lumiliximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-002204-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002204-25.